Introduction {#sec1}
============

A decline in the number of patented novel chemical entities (NCEs) highlights the need for alternative drug discovery approaches ([@ref47]). Target-based drug discovery or *reverse pharmacology* has dominated recent decades. However, the development of more efficient, higher-throughput target-based approaches did not stall this decline ([@ref37]). A renaissance is occurring in the use of phenotype-based drug discovery or *forward pharmacology*, an alternative approach which identifies drugs that change the observable traits of cells or organisms ([@ref48]). Although generally not as efficient as target-based drug discovery, this approach enables unbiased or target-agnostic screening, thereby identifying unanticipated drugs and targets that modulate physiological or pathological phenotypes ([@ref54]; [@ref39]). Furthermore, when performed in whole organisms, the pharmacodynamics, pharmacokinetics, and toxicology of a drug are evaluated in a complex physiological system ([@ref27]; [@ref57]).

Zebrafish is a cost-effective vertebrate model for phenotype-based drug screens ([@ref22]; [@ref58]). Their small size, high fecundity, and large clutches of transparent embryos coupled with rapid and external development consolidate zebrafish as a robust model organism for drug discovery ([@ref31]; [@ref42]). As vertebrates, zebrafish have significant similarity to humans including orthologs of 80% of the expressed genome and ability to investigate features of human physiology and disease (*e.g.,* hematopoiesis, tissue regeneration, cancer, and blindness), therefore providing a robust translational model ([@ref54]; [@ref25]). Phenotype-based readouts include assays of development, behavior, metabolism, and angiogenesis ([@ref35]; [@ref2]; [@ref40]), often applying bespoke reporter or mutant lines. In screens related to angiogenesis, the Tg(*fli1a*:GFP) or Tg(*flk1*:GFP) transgenic lines expressing GFP in all vascular endothelial cells allow facile visualization of vasculature development in specific organs ([@ref24]; [@ref1]; [@ref18]).

Aberrant ocular angiogenesis in diabetic retinopathy (DR) or age-related macular degeneration (AMD) leading to blindness is a major socioeconomic problem ([@ref3]; [@ref10]). Leaky vessels in the eye cause vitreous hemorrhage, retinal detachment, and macular edema, leading eventually to complete loss of vision. The most successful therapies for these vasculopathies are antibodies targeting vascular endothelial growth factor (VEGF) administered directly into the eye ([@ref36]). However, the intraocular injections are expensive and require repeat administration every 4--8 weeks. In addition, the injections are uncomfortable, increase risk of eye infection, and \~50% of patients become nonresponsive, probably due to VEGF-independent resistance ([@ref23]). Thus, small molecule organic chemicals exerting antiangiogenic properties *via* alternative, additive, or synergistic pathways offer potential to be developed as novel stand-alone or combinatorial drugs.

To date, the majority of phenotype-based drug screens in zebrafish test chemical libraries of 1,000--5,000 compounds ([@ref40]). Automated or robotic technology for zebrafish sorting and drug treatment facilitates higher throughput, which then becomes rate limited by the time for analysis ([@ref6]; [@ref52]; [@ref56]; [@ref15]; [@ref5]). As a complementary approach, we applied a "drug pooling" method to enable faster identification of the most promising compounds. In contrast to the "one compound, one well" approach of previous screens, in "drug pooling" combinations of several compounds are tested first in a primary screen and potential hits are confirmed in secondary screens. The rationale behind this approach is that in randomized chemical libraries, only a small fraction (0.6--1.7%) are bioactive compounds and most substances can be quickly identified as inactive *via* negative results of a tested pool ([@ref21]; [@ref9]; [@ref33]; [@ref41]; [@ref46]). By effectively lowering sample numbers when investigating large chemical libraries, this accelerates scientific findings and conducts drug screening in accordance with the 3R principles.

Materials and Methods {#sec2}
=====================

Zebrafish Husbandry {#sec3}
-------------------

The zebrafish transgenic line Tg(*fli1a*:eGFP)^y1^ that expresses enhanced green fluorescent protein (GFP) under the control of an endothelial specific promoter was raised under standard conditions (28°C, pH 7.2--7.4, 14/10 h light/dark cycle) with pH and dissolved oxygen routinely monitored ([@ref24]; [@ref14]). The adult fish was fed twice daily with live ZM Ltd artemia and Lillico zebrafish diet. Zebrafish eggs were collected in 10 cm petri dishes in Hanks embryo medium ([@ref55]). Embryos were staged, and normal development was confirmed under an Olympus stereo microscope (SZX10). All experiments were approved by UCD ethics committee and conducted according to EU directive 2010/63/EU on the protection of animals used for scientific purposes.

Compounds Tested {#sec4}
----------------

The ChemBridge DIVERSet™ library contains compounds with drug like properties, designed with MW ≤500, clogP ≤5, tPSA ≤100, rotatable bonds ≤8, hydrogen bond acceptors ≤10 and hydrogen bond donors ≤5, and an absence of nondrug like chemical groups. A total of 1,760 random small organic molecules of the ChemBridge DIVERSet™ library dissolved in 100% DMSO at a stock concentration of 10 mM were screened as attenuators of zebrafish ocular vasculature development.

Drug Pooling {#sec5}
------------

The DIVERSet™ library compounds were provided as 80 compounds per 96 well plates. To increase screening throughput, 10 compounds of a row or 8 compounds of a column were orthogonally pooled and tested in final concentration of 10 μM per compound in 1% DMSO. The 80 compounds of each plate were thus tested in 18 pools with every compound represented in two different pools ([Figure 1B](#fig1){ref-type="fig"}).

![Method overview for orthogonal drug pooling. **(A)** Overview of drug treatment protocol. Tg(*fli1a*:eGFP) positive embryos were treated from 2--5 dpf and screened for intraocular vascular defects to assess the antiangiogenic potential of test chemicals. Sunitinib was used as positive antiangiogenic control and 1% DMSO as negative vehicle control. **(B)** In each 96 well plate, the 8 compounds of 10 columns and the 10 compounds of 8 rows were assembled in pools (left panel). This orthogonal pooling protocol reduced 80 individual compounds to 18 test pools. Every compound is represented in two pools (right panel). **(C)** The primary hyaloid vessel assay readout assesses the lenses dissected (lower left and middle box) from fixed larvae and quantification of the number of primary hyaloid vessels emerging from the optic disk (asterisk) on the back of the lens counted manually under a stereomicroscope (lower right box). **(D)** In total, 1,760 compounds were analyzed, combined in 396 pools, resulting in one confirmed hit using this method. This assay replaces animal use with immature larval forms and the orthogonal pooling reduces the number of immature larvae needed by 45%.](fphar-10-00508-g001){#fig1}

Drug Treatments and Quantification {#sec6}
----------------------------------

To determine the effect of test drugs on hyaloid vessel (HV) formation, five embryos were treated at 2 days post fertilization (dpf) with single or pooled compounds at a starting concentration of 10 μM in a volume of 400 μL embryo medium ([Figure 1A](#fig1){ref-type="fig"}; [@ref1]; [@ref18]). At 5 dpf, embryos were fixed with 4% PFA and lenses were dissected from the eye to count connected primary hyaloid vessels ([Figure 1C](#fig1){ref-type="fig"}; [@ref1]). To assess inhibition of angiogenesis in the intersegmental vessel (ISV), embryos were treated from 6 to 72 hours post fertilization (hpf). At 1.5 dpf, the ISVs that sprout from the dorsal aorta and elongated dorsally have reached the most dorsal region of the trunk and formed a T shape. Once these vessels connect, they form a pair of dorsal longitudinal anastomotic vessels (DLAV) ([@ref19]). For quantification, all ISVs that reached the most dorsal position and were connected to the DLAV were manually counted as 1. Absent vessels or sprouts without connection to the DLAV were counted as 0. Dead larvae were not considered for quantification. In wells with three or more dead larvae, the combination of drugs was considered "toxic." Unless all compounds of a toxic combination were represented in other nontoxic pools, they were tested again individually. 1% DMSO was used for negative vehicle control in pools and 0.1% DMSO as vehicle control for individual treatments. 10 μM sunitinib (Sigma Aldrich \#PZ0012) was used as positive control ([@ref11]; [@ref17]). The number of blood vessels was determined using an Olympus stereo microscope (SZX10) and representative pictures are taken using Olympus DP71 camera and CellSens Standard software ([Figure 1C](#fig1){ref-type="fig"}).

Statistical Analysis {#sec7}
--------------------

We wish to assess whether the means of two groups are statistically different from each other. An independent sample *t* test will evaluate if the data support this claim but requires that the population of the sample is approximately normally distributed within each group and the population variances of the two groups are equal. We use a Shapiro-Wilk test to assess whether the sample is drawn from a population with a normal distribution and a Fligner-Killeen test to determine if the variances of the two populations are equal. If the Shapiro-Wilk test and the Fligner-Killeen test hypotheses are not rejected, then an independent sample *t* test is appropriate. If only the hypothesis of the Fligner-Killeen test is rejected, a *t* test adjusted for unequal variance (Welch's t-test) is appropriate. If the hypothesis of the Shapiro-Wilk test is rejected, then a Mann-Whitney *U* test is suitable. For each test, if *p* \< 0.05, we reject the null hypothesis and conclude there is evidence of a significant difference between the groups (\**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001).

Results {#sec8}
=======

Orthogonal Drug Pooling {#sec9}
-----------------------

We decided on an orthogonal pooling strategy to evaluate both the feasibility and benefits of drug pooling for identification of library chemicals that attenuate hyaloid vessel development ([Figure 1](#fig1){ref-type="fig"}). Our pooling strategy combined 10 drugs of each plate row (*e.g.,* pool H) and 8 drugs from each plate column (*e.g.,* pool 5) into single pools ([Figure 1B](#fig1){ref-type="fig"}) with a final concentration of 1% DMSO. This ensured that every compound was present in at least two pools (*e.g.,* H5 in pool H and pool 5), making it easier to distinguish true positives. As a phenotype-based readout for antiangiogenic activity, we counted the number of primary hyaloid vessels in lenses dissected from five dpf eyes of Tg(*fli1a*:eGFP) embryos, following 3 days of drug treatment ([Figure 1C](#fig1){ref-type="fig"}). Sunitinib, a potent multi-tyrosine kinase inhibitor with known antiangiogenic properties at 10 μM, was used as positive control. This method allows testing of 80 compounds from one 96-well plate in 18 pools or the library of 1,760 compounds (22 plates) to be tested in 396 pools ([Figure 1D](#fig1){ref-type="fig"}).

Proof of Principle {#sec10}
------------------

We first determined if the final pool concentration of 1% DMSO may non-specifically generate an antiangiogenic phenotype. In a dose-response analysis (ranging from 0.1--3%) DMSO, concentrations up to 2% DMSO had no effect on primary HV (PHV) formation ([Figure 2A](#fig2){ref-type="fig"}). To implement and validate the adopted method, we first pooled 10 compounds of row D and 8 compounds of column 4 from randomly chosen Diverset® plate \#30331 ([Figure 2B](#fig2){ref-type="fig"}). Pool 4 (3.0 ± 1.0 PHV) was indistinguishable from the vehicle controls (3.5 ± 0.6 PHV) ([Figure 2B](#fig2){ref-type="fig"}). Pool D induced a slight (2.6 ± 0.5 PHV) but significant (*p* \< 0.05) reduction by 25% in hyaloid vessel number ([Figure 2B](#fig2){ref-type="fig"}). None of the ten constituent compounds (D2-D11) from pool D exerted a significant antiangiogenic effect on their own; however, D3 by itself reduced hyaloid vessel (2.8 ± 0.5 PHV or 21% reduction) similar to pool D ([Figure 2B](#fig2){ref-type="fig"}). In contrast, when compound D4 was replaced with 10 μM sunitinib in pool D or pool 4, robust antiangiogenic activity (0.2 ± 0.4 PHV, 94% reduction) was observed, equivalent to treating with 10 μM sunitinib alone (0.3 ± 0.5 PHV, 91% reduction). We conclude that active antiangiogenic compounds can be detected in our drug pooling screen.

![Proof-of-Principle. **(A)** Effect of DMSO concentration on HV assay. 1% DMSO vehicle has no effect on HV numbers. **(B)** The compounds of row D (D2-D11) and column 4 (4A-4H) in plate \#30331 were tested individually and as pools. When 10 μM sunitinib was added to the pool "D" or "4" (pool D + Sun or pool4 + Sun), its antiangiogenic effects were as pronounced as if tested on its own (Sunitinib). **(C)** When compounds of plate \#30251 were tested in pools, well H4 which was replaced with 10 μM sunitinib, was easily detected as antiangiogenic in both pools ("H" & "4") containing H4. **(D)** A dose--response analysis with different concentrations of sunitinib alone or added to pool D in plate \#30331 proves that weaker antiangiogenic effects can be reliably detected in pools. Shown are representative bright-field images of larvae, corresponding fluorescent images of dissected lenses and the quantification of primary hyaloid vessel numbers (right). Data shown are means ± SD. Statistical significance was calculated by *t* test and Mann Whitney test (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\* *p* \< 0.001).](fphar-10-00508-g002){#fig2}

To scale-up the *proof-of-concept* screen, we tested all 80 compounds of randomly chosen Diverset® plate \#30251 in 18 pools ([Figure 2C](#fig2){ref-type="fig"}). Compound H4 was replaced with 10 μM sunitinib as a positive control. Reassuringly, pools H and 4, which contain 10 μM sunitinib, were true positives resulting in 0.2 ± 0.4 and 0.4 ± 0.5 primary hyaloid vessels reflecting a 93 and 87% reduction, respectively. There was a clear efficacy difference between these pools and the nonspiked, inactive pools ([Figure 2C](#fig2){ref-type="fig"}).

To address the concern that pooling compounds might mask active compounds, we performed a dose-response curve for sunitinib to determine if the concentration at which sunitinib no longer produced significant antiangiogenic activity was different when administered alone compared to in D pools from Diverset® plate \#30331 ([Figure 2D](#fig2){ref-type="fig"}). Larvae treated with pool D alone were indistinguishable (2.8 ± 0.4 PHV, *p* \> 0.6) from 1% DMSO vehicle controls. In general, the activity of sunitinib was equivalent in pools or alone, producing robust, significant antiangiogenic activity at 5 and 10 μM concentrations ([Figure 2D](#fig2){ref-type="fig"}). At 2.5 μM, sunitinib showed a significant reduction (*p* \< 0.05) in hyaloid vessel number in the pool and not with sunitinib alone (*p* \> 0.1), and the fold reduction was significantly different (0.6 ± 0.9 and 2.2 ± 0.8 PHV). This was also reflected in embryo morphology with edema present when treated with 1 μM sunitinib in pool D but not with 1 μM sunitinib alone and more severe edema forming at 2.5 μM sunitinib in pool D than with 2.5 μM sunitinib alone ([Figure 2D](#fig2){ref-type="fig"}). In conclusion, our combinatorial approach was sufficient to identify antiangiogenic compounds present in drug pools.

Self-Deconvoluting Library Screen {#sec11}
---------------------------------

Theoretically, every active compound should present in two pools (one row and one column). We additionally applied a cutoff of at least 40% reduction on primary hyaloid vessels number to be considered a hit. Smaller reductions were considered more likely to be false positives due to combinatorial effects. In the pooling screen, we tested 396 pools, representing 1,760 compounds, for antiangiogenic efficacy in the hyaloid vessel assay. Analysis of Diverset® plate \#30328 depicts a representative screen result ([Figure 3A](#fig3){ref-type="fig"}). In that plate, less than three larvae survived treatment in four pools (\#30328 A, H, 4, 7). When compounds A4, A7, H4 and H7 were re-tested individually, none showed efficacy or toxicity ([Figure 3B](#fig3){ref-type="fig"}). Notably, three of 18 pools (\#30328 D, G & 9) showed a significant reduction in HV vessel numbers ([Figure 3A](#fig3){ref-type="fig"}). Two pools exceeded our threshold of 40% PHV reduction (\#30328G 75% reduction, *p* \< 0.05 and \#30328--9 88% reduction, *p* \< 0.01; [Figure 3A](#fig3){ref-type="fig"}). To determine if a single compound present in pools G and 9 was responsible for the reduction in PHV, the 17 constituent compounds were tested individually. Compound G9 (chemical name: 4-(2,4-dichlorophenoxy)-N,N-diethyl-1-butanamine) initially reproduced significant antiangiogenic activity but upon repeat testing in dose-response assays, its activity-toxicity profile was highly variable and was eliminated from further follow-up ([Figures 3C](#fig3){ref-type="fig"}--[E](#fig3){ref-type="fig"}).

![Self-deconvoluting library screen. **(A)** The screen of plate \#30328 is shown as a representative example where 80 drugs (A2-H11) were analyzed in 18 pools (A-H, 2--11). 4 pools were lethal to the embryos (A, H, 4, 7). Three pools showed a significant reduction in blood vessel numbers, but only two (G, 9) exceeded the threshold of 40% reduction in HV numbers. **(B)** Individually re-tested compounds from toxic pools or of pool hits from plate \#30328 identified G9 as promising candidate for further testing with \>40% PHV reduction. **(C)** Representative images from DMSO control or 10 μM G9 treated zebrafish lenses showing the GFP-positive hyaloid vessels. **(D)** Three independent dose curves (test1--3) of G9 drug treatments showed strong toxicity at concentrations of \>5 μM and lack of reproducible antiangiogenic activity. **(E)** The chemical structure of and chemical name (4-(2,4-Dichlorophenoxy)-N,N-diethyl-1-butanamine) of G9. **(F)** Individual re-testing of all 80 compounds from plate \#30325 that were toxic in pools. No single compound reduced HV \>40% and 2 were lethal at 10 μM (10G, 11B). **(G)** Summary of library screen. Pooled drug screens were conducted for 22 plates containing 1,760 different compounds. In 63% of cases, combinations of 8 or 10 pooled drugs did not reduce HV numbers \>40%. 22% of pools caused significant developmental defects or were lethal. Of the 147 compounds identified in 18 pool hits, 80% had no significant effect when tested individually, two were toxic and eight were considered hits that significantly reduce hyaloid vessel number. Data in **(A)**, **(B)**, **(D)**, and **(F)** are means ± SD. Statistical significance calculated by *t* test and Mann Whitney test (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001).](fphar-10-00508-g003){#fig3}

In contrast to plate \#30328, treatment of larvae with pooled compounds of plate \#30325 resulted in larval death of 50% and severe developmental problems in all remaining wells. Consequently, all 80 compounds of that plate were tested individually ([Figure 3F](#fig3){ref-type="fig"}). Two compounds produced significant antiangiogenic activity (7A, 7D with PHV 2.3 ± 0.5, 2.4 ± 0.5 and *p* 0.01 and 0.015, respectively), three resulted in a significant increase in primary hyaloid vessels (4G, 5H, 8B with PHV 3.8 ± 0.4, 3.8 ± 0.4, 4.2 ± 0.8 and all with *p* values of 0.01) and two were toxic (10G, 11B). None of the significant changes was greater than our selected threshold of 40% and therefore not considered a hit.

In total, of the 396 pools screened, 63% did not surmount the selected threshold of at least 40% PHV reduction compared to the control ([Figure 3G](#fig3){ref-type="fig"}) and were dismissed. More problematic was the 89 or 22% toxic pools, wherein survival rates were under 50% ([Figure 3G](#fig3){ref-type="fig"}). Notably, these predominantly originate from 5 plates with 55 toxic pools and an additional 12 plates with 34 toxic pools ([Figure 3G](#fig3){ref-type="fig"}). To test all of the constituent compounds would require testing 427 individual drugs. In practice, we tested 134 individual drugs from toxic pools and 7% of them showed toxicity and none exerted significant antiangiogenic activity. In total, 24 pools reduced primary HV by greater than 40% ([Figure 3G](#fig3){ref-type="fig"}). Six of these had no corresponding hit in an orthogonal pool and were dismissed as false positives. The remaining 18 pools comprised of 147 compounds that were selected for individual testing ([Figures 3B](#fig3){ref-type="fig"},[G](#fig3){ref-type="fig"} right panel). In second round screens, eight drug hits were identified but seven of them did not exert a dose-dependent antiangiogenic activity in tertiary screens.

Significantly, compound 30238-G5 showed antiangiogenic activity when re-tested individually in secondary HV assays and also demonstrated a dose-dependent response at concentrations between 1 and 20 μM in tertiary screens ([Figures 4A](#fig4){ref-type="fig"}--[C](#fig4){ref-type="fig"}). At 10 and 20 μM, G5 caused primary HV numbers to reduce by 25 or 50%, respectively, with no observed adverse effect on survival or overall morphology ([Figure 4C](#fig4){ref-type="fig"} left panel). When tested in the alternative inter-segmental vessel (ISV) assay, G5 was inactive indicating a specific antiangiogenic effect in the eye ([Figure 4D](#fig4){ref-type="fig"}).

![Identification and confirmation of Hit G5. **(A)** G5 was a promising hit identified in the screen of DIVERSet™ library plate \#30238. **(B)** The chemical structure and chemical name (4-\[4-(1H-benzimidazol-2-yl)phenoxy\]aniline) of hit G5. **(C)** G5 shows a dose-dependent and robust reduction of primary hyaloid vessels at 10 and 20 μM. In addition, at higher doses treated larvae show no difference in survival rates and had only mild morphological changes compared to vehicle control treatments. **(D)** In contrast, G5 had no significant antiangiogenic effect in the ISV assay at the same range of concentrations. Data are means ± SD. Statistical significance calculated by *t* test and Mann Whitney test (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001).](fphar-10-00508-g004){#fig4}

Metrics {#sec12}
-------

Our approach enabled screening of 1,760 compounds of the DIVERSet™ library in only 970 treatments. A prescreen concern with pooling was toxicity levels. We expected from our previous experience with nonpooling screens that 2--5% of test compounds are lethal at 10 μM ([@ref9]; [@ref28]). This predicted an average of 2--4 toxic drugs per plate, which could be represented in 3--8 of the pools (expected toxicity of 17--44%). In practice, the 22% observed toxicity was lower than expected. Another pre-screen concern was the expected higher variation between technical replicates, but the Fligner-Killeen test showed no difference in variation between groups treated with one drug or a drug pool. Based on the screen metrics, the effect of the pooling strategy on sample sizes was calculated for three different libraries (100, 1,000, or 10,000 compounds) and three scenarios with the same, none, or even higher toxicity as experienced in our library screen to demonstrate the usefulness of this method for other screens especially with larger libraries ([Table 1](#tab1){ref-type="table"}). Notably, this pooling approach significantly reduced the required workload ([Table 2](#tab2){ref-type="table"}). This screen required 534 person hours to be completed. The single most time-consuming step (50% time) was needed for the eye dissection and blood vessel quantification, which took \~15 min per well. The remaining time was used for setting up the fish mating (\~6 min/well), collecting, sorting, and distributing embryos to the wells of the plate (\~3 min/well), preparing the drug pools (\~5 min/well), and applying the treatment (\~1 min/well). In this respect, drug-pooling demonstrated its usefulness by effectively lowering sample numbers and reducing the associated time needed for analysis and not just reducing the time for screen set-up and execution as benefitted by other approaches. As a nonpooling approach would have required at least twice the number of treatments tested and analyzed, we calculate that the required time and costs incurred would have doubled if no pooling strategy was applied.

###### 

Effect of orthogonal pooling.

  \# of compounds to be tested      1,760      100       1,000     1,000     1,000     10,000
  --------------------------------- ---------- --------- --------- --------- --------- -----------
  \# of pools needed                396        23        225       225       225       2,250
  \# of toxic pools                 89 (22%)   5         0         51        113       505
  \# of re-tested toxic samples     427        24        0         243       540       2,426
  \# of pooled hits                 18 (5%)    1         10        10        10        102
  \# of re-tested hit samples       147        8         84        84        84        835
  Sum of tests to complete screen   **970**    **55**    **309**   **551**   **848**   **5,511**
  Reduction in samples              **45%**    **45%**   **69%**   **45%**   **11%**   **45%**

Applying the screen metrics, the effect of the pooling strategy on sample size was calculated for three different sized libraries (100, 1,000, or 10,000 compounds) and with 0%, 22 and 50% toxic pools.

###### 

Treatment reduction by orthogonal pooling.

  Type of screen                 Pooled                  Single
  ------------------------------ ----------------------- -------------------------
  Initial screen                 396 pools               1,760 single treatments
  Re-testing from toxic pools    427 single treatments   
  Confirmation of initial hits   147 single treatments   
  Sum                            970                     1,760
  Embryos needed (5/well)        4,850                   8,800
  Reduction in animal numbers    45%                     

Summary of the number of immature larval zebrafish utilized for orthogonal pooled versus single "one compound, one well" approach.

Discussion {#sec13}
==========

Phenotype-based drug screening is still the most productive approach to discover *first-in-class* drugs ([@ref48]; [@ref60]; [@ref53]; [@ref29]). Zebrafish is a prolific vertebrate model for forward pharmacology combining high predictive power with throughput ([@ref34]; [@ref44]; [@ref40]; [@ref58]; [@ref43]). With a rapidly expanding suite of transgenic, knockout, and knockin lines available accelerated by gene editing technology, ever more sophisticated assay endpoints in zebrafish are applicable to phenotype-based screens ([@ref2]; [@ref20]; [@ref26]; [@ref43]). A number of phenotype-based screens in zebrafish, testing single drugs, discovered or validated antiangiogenic small molecule drugs ([@ref50]; [@ref22]; [@ref41]; [@ref7]). Notably, many hits are also antiangiogenic in mammalian models, indeed several are market authorized for clinical use in humans ([@ref8]; [@ref41]; [@ref42]).

Our aim was to increase the efficiency of unbiased chemical screens in zebrafish. In particular, our objective was to more effectively screen a randomized chemical library to identify hits with antiangiogenic activity in the eye. Prior experience in randomized chemical library screening estimated that less than 1% of test drugs are true hits ([@ref41]). A *"one compound, one well"* approach was too time-consuming. An adaptive pooling strategy where every compound is tested in only one pool increased the risk of false negatives. Thus, our approach was to treat *Tg(fli1a:eGFP)* zebrafish larvae with 8 or 10 drugs simultaneously, applying an orthogonal pooling strategy wherein every compound is represented in two pools ([@ref30]; [@ref21]; [@ref32]). Selection of this strategy was based on the following rationale: (1) most randomized chemical library compounds are inactive in a given assay, (2) robust inhibitors of angiogenesis can retain activity in drug pools, and (3) orthogonal pooling would lower the likelihood of false positive or negatives due to synergistic or antagonistic effects ([@ref12]; [@ref51]).

Typically, we screen drugs in the presence of 0.1% DMSO ([@ref45]; [@ref41]; [@ref49]). As the DIVERSET® compounds are provided at 10 mM stock in 100% DMSO, we confirmed at the outset that the 1% DMSO concentration in all pools did not elicit toxic/pharmacological effects on hyaloid vasculature development. In accordance with previous investigations, we did not observe an adverse effect of 1% DMSO on larval zebrafish development ([Figure 2B](#fig2){ref-type="fig"}) ([@ref16]; [@ref59]). Overall, toxicity affected 22% of the pools representing 24% of compounds in the screen. In contrast, only 3% of single drug treated resulted in toxicity. This suggests that the toxic effects arise from the drug combinations more than individual drugs, due to additive or synergistic effects causing higher toxicity ([@ref13]). Generally, zebrafish embryos are a good model for predicting toxicity, and testing on whole organisms can prevent more costly drug failure setbacks with off-target effects later in drug development ([@ref38]). Despite an increased toxicity, resulting in 424 samples requiring re-testing, the sample numbers (immature larvae) required for the pooling approach were reduced by 45% compared to a "*one compound, one well*" approach ([Table 2](#tab2){ref-type="table"}). Therefore, our pooling screen in immature zebrafish larvae replaces the use of animals and significantly reduces the number of immature animal forms tested, in accordance with the 3R principles ([@ref4]). For libraries with less bioactive substances or tested at lower concentrations, a theoretical sample size reduction of 69% is possible ([Table 1](#tab1){ref-type="table"}). Even if twice the number of pools were impossible to analyze due to toxicity and 50% of the samples had to be re-analyzed individually, the overall sample size would reduce by 11%. Testing in drug pools was expected to cause higher variation in results from replicates. However, the statistical analysis showed no significant difference in variation of groups treated with one drug or a drug pool. Still, we concentrated our efforts on compounds with a high threshold of 40% reduction of primary hyaloid vessel numbers to be considered a hit. This design strategy was successful in screening for antiangiogenic drugs.

In conclusion, phenotype-based drug screening in zebrafish remains a powerful approach for drug discovery. Orthogonal drug pooling strategies can easily be applied to other screening paradigms in zebrafish. Orthogonal drug pooling increases screening throughput and reduces sample numbers requirements, significantly saving time and costs and complying with the 3R principles.
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